Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 15/20 | 0.53 |
| ▸ | CTNNB1 | P35222 | 15/20 | 0.53 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12013118 | 0.95 | BCL9 (0.51) | BCL9CTNNB1CACNA1BGAAHPGD | |
| SCHEMBL478185 | 0.93 | BCL9 (0.49) | BCL9CTNNB1CACNA1BPSEN1PSEN2 | |
| SCHEMBL478136 | 0.91 | BCL9 (0.53) | BCL9CTNNB1CACNA1BGAAHPGD | |
| SCHEMBL12012780 | 0.91 | BCL9 (0.53) | BCL9CTNNB1CACNA1BGAAHPGD | |
| SCHEMBL478138 | 0.89 | PSEN1 (0.46) | BCL9CTNNB1GAAPSEN1PSEN2 | |
| SCHEMBL478135 | 0.88 | BCL9 (0.46) | BCL9CTNNB1GAAPSEN1PSEN2 | |
| SCHEMBL478119 | 0.84 | BCL9 (0.42) | BCL9CTNNB1 | |
| SCHEMBL478039 | 0.84 | PSEN1 (0.56) | BCL9CTNNB1CACNA1BPSEN1PSEN2 | |
| SCHEMBL478285 | 0.84 | PSEN1 (0.47) | BCL9CTNNB1PSEN1PSEN2APH1B | |
| SCHEMBL478055 | 0.84 | PSEN1 (0.48) | BCL9CTNNB1PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252935-B2 | Piperidinyl and piperazinyl modulators of γ-secretase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-28 | — | — | US | disclosed |
| US-8252935-B2 | Piperidinyl and piperazinyl modulators of γ-secretase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-28 | — | — | US | disclosed |
| EP-2212287-B1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-01 | — | — | EP | disclosed |
| EP-2212287-B1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-01 | — | — | EP | disclosed |
| EP-2212287-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | Janssen Pharmaceutica, N.V. (BE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009052126-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF γ-SECRETASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052126-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF γ-SECRETASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | disclosed |
| US-20090105275-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105275-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105275-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | BACE1, BACE2, PSEN1 | BCL9 637/4885CTNNB1 2518/4885CACNA1B 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.